2 terminated, 1 active not recruiting, 1 completed. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Terminated 2, Active not recruiting 1, Completed 1 |
Follow Td-9855: new trials by email Literature Review of Td-9855 trials Research Report on Td-9855
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy Ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | Phase 3 | Active not recruiting | Theravance Biopharma | 102 | 2023-06-27 | 2025-09-05 |
| Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure ampreloxetine - Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | Terminated | Theravance Biopharma | 110 | 2019-09-19 | 2022-11-30 |
| Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension, MSA | Phase 3 | Terminated | Theravance Biopharma | 203 | 2019-02-22 | 2023-01-20 |
| Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | Completed | Theravance Biopharma | 195 | 2019-01-24 | 2022-09-14 |
Dizziness (3) · Hypotension (3) · Parkinson Disease (3) · Pure Autonomic Failure (3) · Syncope (3) · Hypotension, Orthostatic (2) · Parkinsonian Disorders (2) · Multiple System Atrophy (1) · Shy-Drager Syndrome (1)
Australia (4) · Austria (4) · Canada (4) · Denmark (4) · Estonia (4) · France (4) · Germany (4) · Israel (4) · Italy (4) · New Zealand (4) · Poland (4) · Portugal (4) · Spain (4) · United Kingdom (4) · United States (4)
2018 (2), 2019 (1)